AS Freeman in the news
If you were unable to attend MPO’s 2025 Medtech Forum in Costa Rica, you can now view the sessions on-demand on the MPO Site. The archive is here, with my presentation being Session 2: State of the Industry. You may find the slides from my talk here. Please contact me with any comments or questions.
In my latest column for MPO, I discuss the risks new weight-loss drugs (GLP1s) may pose to OEMs and contract manufacturers. Heavy Harm or Slim Chance? The Impact of GLP1s on Medtech The highest existential risk is not to OEMs but to contract manufacturers specializing in the areas where GLP1s will delay surgeries. Read the column here.
I am honored to present The State of the Medtech Industry keynote address on October 18th at the MPO Summit in San Diego. I’ll cover the forces changing product lines and potentially introducing new competitors into the medtech supply chain.
Atalys has acquired precision moldmaker ROMOLD, Inc. of Rochester, New York. A.S. Freeman Advisors, LLC advised ROMOLD on this transaction. For more information please contact Tony Freeman. Anthony S. Freeman A.S. Freeman Advisors, LLC (917) 868-0772 tfreeman@asfreeman.com asfreeman.com
My latest piece for MPO Magazine discusses business strategies for the medical device supply chain in response to two trends: the rise of reliance on contract manufacturers vs OEMs, and supply chain consolidation.
Two strategies have emerged: the integrated contract manufacturer approach, and the specialist niche approach. I discuss the advantages and disadvantages of each, and opportunities for strategic expansion.